Stockreport

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data ant [Read more]